Study Reports Marijuana Use Among Patients With Cancer May Be Increasing While Opioid Use Stays Stable, but Questions Remain
The proportion of participants with cancer who used marijuana increased 118% from the period of 2005 to 2014.
Bone Cancer
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Wider Use of Basket Trials Could Hasten Development of Precision Therapies
Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration.
Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site
The study showed little value for the molecular assay in improving outcomes, but several weaknesses may have undermined the investigation.
Chemotherapy-Stimulated Immune Response: An Open Debate
Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.
FDA Calls for Patient Registries to Track Robotically Treated Cancers
Head-to-head comparisons of these types of surgical interventions are still needed, according to the regulatory body.
Next post in General Oncology
